iBio
iBio is a biotechnology company that provides contract development and manufacturing services for biologics to collaborators and third-party customers in the United States. Its lead therapeutic programs include IBIO-100 for systemic sclerosis and idiopathic pulmonary fibrosis, along with vaccine candidates IBIO-200 and IBIO-201 (preclinical for SARS-CoV-2) and IBIO-400 for classical swine fever; it also develops recombinant proteins for catalog and custom use and offers process development, manufacturing, filling and finishing, and analytical services. The company operates platforms such as iBioLaunch and iBioModulator, which enable plant-based production of biologics through transient expression, supporting rapid development and scalable facilities. It also leverages AI to guide antibody design and optimization. iBio maintains multiple collaborations and licenses with Planet Biotechnology, AzarGen Biotechnologies, the Texas A&M University System, and the University of Natural Resources and Life Sciences, Vienna, along with partnerships with EdgePoint AI and CC-Pharming. Headquartered in New York, iBio positions itself as a CDMO and AI-enabled biotechnologies provider.
Top Regions
Top Stages
2 past transactions
RubrYc Therapeutics
Acquisition in 2022
RubrYc Therapeutics Inc. is a biotechnology company based in San Carlos, California, founded in 2017. The company focuses on the integration of chemistry and computation to decode protein interfaces, which facilitates the discovery of antibody-based drugs with selectivity for specific epitopes. By leveraging advancements in molecular library synthesis and massively parallel screening, RubrYc Therapeutics aims to revolutionize the design and development of therapeutic antibodies. Its innovative approach provides partners in the biotherapeutic field with tools to accelerate preclinical antibody discovery while reducing the risks typically associated with traditional drug discovery methods.
RubrYc Therapeutics
Series A in 2021
RubrYc Therapeutics Inc. is a biotechnology company based in San Carlos, California, founded in 2017. The company focuses on the integration of chemistry and computation to decode protein interfaces, which facilitates the discovery of antibody-based drugs with selectivity for specific epitopes. By leveraging advancements in molecular library synthesis and massively parallel screening, RubrYc Therapeutics aims to revolutionize the design and development of therapeutic antibodies. Its innovative approach provides partners in the biotherapeutic field with tools to accelerate preclinical antibody discovery while reducing the risks typically associated with traditional drug discovery methods.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.